Jay Flatley – Juno Therapeutics

Jay Flatley


Jay Flatley is Executive Chairman of Illumina, Inc., the global leader in DNA sequencing and array-based technologies. Previously, Mr. Flatley led Illumina as Chief Executive Officer from 1999 to 2016. Prior to his time at Illumina, Mr. Flatley served as President and Chief Executive Officer of Molecular Dynamics, where he was a co-founder and member of the Board of Directors. He led Molecular Dynamics to its initial public offering in 1993 and helped the company develop and launch over 15 major instrumentation systems. Prior to joining Molecular Dynamics, Jay was Vice President of Engineering and Strategic Planning for Plexus Computers, Executive Vice President for Manning Technologies and held various positions at Spectra Physics. Mr. Flatley chairs the Board of Directors for Illumina subsidiary, Helix. He also serves as an Advisory Board member for UC San Diego’s Moore Cancer Center, as well as a Board of Director at Coherent and Denali, and on the Board of Trustees of the Salk Institute. Mr. Flatley received a B.A. in economics from Claremont McKenna College and a B.S. and M.S. in industrial engineering from Stanford University.